mAbxience |
Insud Pharma donation and assistance – Ukraine war situation
03/07/2022
At Insud Pharma we are deeply concerned about the war situation in Ukraine, hoping for a fast, peaceful resolution as soon as possible. Our thoughts are with everyone affected by this war and with the people who are suffering and fearing for their lives and livelihood. From the beginning, we are in continuous contact with […]
mAbxience launches its CDMO platform to third parties
02/28/2022
mAbxience, an experienced, specialized global biotechnology company, aims to leverage its capacity, expertise and proven track record in the optimization of biologic development & manufacturing programs for third parties. With a global mission to make biologic medicines accessible and affordable across the globe, mAbxience aims to focus its core expertise to accelerate and transform current […]
mAbxience’s biosimilar approved in Japan
02/23/2022
Nichi-Iko Pharmaceutical Co., Ltd. has recently announced that it received approval for a biosimilar of bevacizumab BS intravenous infusion 100 mg/400 mg, whose marketing authorization application was filed based on the clinical pharmacokinetic (PK) study data conducted in Japan in addition to the global Phase 3 study data conducted by mAbxience. Bevacizumab BS is highly […]
PAHO selects centers in Argentina, Brazil to develop COVID-19 mRNA vaccines
10/25/2021
Washington DC, September 21, 2021 (PAHO) – The Pan American Health Organization (PAHO) has announced the selection of two centers in Argentina and Brazil as regional hubs for the development and production of mRNA-based vaccines in Latin America in a bid to tackle COVID-19 and future infectious-disease challenges. The Bio-Manguinhos Institute of Technology on Immunobiologicals […]
European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of Cancer
03/31/2021
The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe.
Spain’s mAbxience boosting biologics capacity with 4,000 L SUB
03/25/2021
Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most processes.” Now the site […]